It aims to combat metabolic syndrome and the associated type 2 diabetes, according to the "Science in Siberia" bulletin.
Metabolic syndrome is defined as a group of metabolic disorders that increase the risk of serious diseases, such as type 2 diabetes, cardiovascular disease, and atherosclerosis. It includes obesity, impaired carbohydrate and fat metabolism, and high blood pressure.
The innovative drug consists of a molecule extracted by combining a phenylpropanoic acid derivative with terpenoids. It targets and activates nuclear PPAR receptors, which are responsible for regulating carbohydrate and lipid metabolism. Scientists based the development of this compound on a clinically active phenylpropanoic acid fraction, to which they added natural compounds from birch bark and pine resin, and monoterpenes from essential plant oils.
Experiments on genetically modified mice showed that the compounds lowered blood glucose and cholesterol levels without negatively affecting liver enzymes. The drug also has a cumulative effect, making it more effective than short-acting medications used to treat diabetes.
Scientists are currently continuing molecular and genetic cell studies in collaboration with the Federal Research Center “Institute of Cytology and Genetics” to assess the compound’s effectiveness and future therapeutic potential.